BioWorld

July 2, 2009

View Archived Issues

No Buyout, but Acorda Banks $110M in Fampridine-SR Deal

It wasn't the acquisition some investors had hoped for, but Acorda Therapeutics Inc. hardly could have asked for better terms in its ex-U.S. licensing deal for multiple sclerosis drug Fampridine-SR. (BioWorld Today) Read More

Myriad's Lowered Guidance Casts Pall over Spin-off Debut

Read More

Risk Genes for Schizophrenia Aplenty; Bipolar Shares Some

Read More

Biotech Survival Game Prompts CombinatoRx, Neuromed Merger

Read More

Holiday Notice

Read More

Awaiting FDA Action on Zevalin, Spectrum Seeks to Raise $21M

Read More

Clinic Roundup

Read More

Other News To Note

Read More